Literature DB >> 25268700

Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.

Anil Kumar Jaiswal1, Prashant Khare1, Sumit Joshi1, Pramod Kumar Kushawaha1, Shyam Sundar2, Anuradha Dube1.   

Abstract

In visceral leishmaniasis, the recovery from the disease is always associated with the generation of Th1-type of cellular responses. Based on this, we have previously identified several Th1-stimulatory proteins of Leishmania donovani -triose phosphate isomerase (TPI), protein disulfide isomerase (PDI) and elongation factor-2 (EL-2) etc. including heat shock protein 70 (HSP70) which induced Th1-type of cellular responses in both cured Leishmania patients/hamsters. Since, HSPs, being the logical targets for vaccines aimed at augmenting cellular immunity and can be early targets in the immune response against intracellular pathogens; they could be exploited as vaccine/adjuvant to induce long-term immunity more effectively. Therefore, in this study, we checked whether HSP70 can further enhance the immunogenicity and protective responses of the above said Th1-stimulatory proteins. Since, in most of the studies, immunogenicity of HSP70 of L. donovani was assessed in native condition, herein we generated recombinant HSP70 and tested its potential to stimulate immune responses in lymphocytes of cured Leishmania infected hamsters as well as in the peripheral blood mononuclear cells (PBMCs) of cured patients of VL either individually or in combination with above mentioned recombinant proteins. rLdHSP70 alone elicited strong cellular responses along with remarkable up-regulation of IFN-γ and IL-12 cytokines and extremely lower level of IL-4 and IL-10. Among the various combinations, rLdHSP70 + rLdPDI emerged as superior one augmenting improved cellular responses followed by rLdHSP70 + rLdEL-2. These combinations were further evaluated for its protective potential wherein rLdHSP70 + rLdPDI again conferred utmost protection (∼80%) followed by rLdHSP70 + rLdEL-2 (∼75%) and generated a strong cellular immune response with significant increase in the levels of iNOS transcript as well as IFN-γ and IL-12 cytokines which was further supported by the high level of IgG2 antibody in vaccinated animals. These observations indicated that vaccine(s) based on combination of HSP70 with Th1-stimulatory protein(s) may be a viable proposition against intracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25268700      PMCID: PMC4182492          DOI: 10.1371/journal.pone.0108556

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  94 in total

Review 1.  Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses.

Authors:  K M Anderson; P K Srivastava
Journal:  Immunol Lett       Date:  2000-09-15       Impact factor: 3.685

2.  Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.

Authors:  Pramod K Kushawaha; Reema Gupta; Shyam Sundar; Amogh A Sahasrabuddhe; Anuradha Dube
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

3.  Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

Authors:  R X Armijos; M M Weigel; M Calvopina; A Hidalgo; W Cevallos; J Correa
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

Review 4.  The perfect mix: recent progress in adjuvant research.

Authors:  Bruno Guy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

5.  Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.

Authors:  Farhat Afrin; Ravindran Rajesh; Khairul Anam; Meenakshisundram Gopinath; Swati Pal; Nahid Ali
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure.

Authors:  A Hailu; J N Menon; N Berhe; L Gedamu; T H Hassard; P A Kager; J Olobo; P A Bretscher
Journal:  J Infect Dis       Date:  2001-05-31       Impact factor: 5.226

Review 7.  Heat shock protein--peptide complexes as immunotherapy for human cancer.

Authors:  D Przepiorka; P K Srivastava
Journal:  Mol Med Today       Date:  1998-11

8.  CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.

Authors:  Sanjai Kumar; Trevor R Jones; Miranda S Oakley; Hong Zheng; Shanmuga P Kuppusamy; Alem Taye; Arthur M Krieg; Anthony W Stowers; David C Kaslow; Stephen L Hoffman
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.

Authors:  Shraddha Kumari; Mukesh Samant; Prashant Khare; Shyam Sundar; Sudhir Sinha; Anuradha Dube
Journal:  Vaccine       Date:  2008-07-24       Impact factor: 3.641

10.  Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis.

Authors:  Pramod Kumar Kushawaha; Reema Gupta; Chandra Dev Pati Tripathi; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

View more
  11 in total

1.  A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Daysiane de Oliveira; Bethina T Steiner; Vívian T Martins; Luísa Perin; Amanda S Machado; Thaís T O Santos; Grasiele S V Tavares; João A Oliveira-da-Silva; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Antônio L Teixeira; Maria V Humbert; Eduardo A F Coelho; Myron Christodoulides
Journal:  NPJ Vaccines       Date:  2020-08-13       Impact factor: 7.344

Review 2.  Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis.

Authors:  Sajad Rashidi; Kurosh Kalantar; Gholamreza Hatam
Journal:  J Parasit Dis       Date:  2018-03-19

3.  SjHSP70, a recombinant Schistosoma japonicum heat shock protein 70, is immunostimulatory and induces protective immunity against cercarial challenge in mice.

Authors:  Ming Ming Duan; Rui Min Xu; Chun Xiu Yuan; Yun Yan Li; Qun Liu; Guo Feng Cheng; Jiao-Jiao Lin; Xin Gang Feng
Journal:  Parasitol Res       Date:  2015-06-21       Impact factor: 2.289

4.  An immunoproteomic approach to identifying immunoreactive proteins in Leishmania infantum amastigotes using sera of dogs infected with canine visceral leishmaniasis.

Authors:  Sajad Rashidi; Zahra Mojtahedi; Bahador Shahriari; Kurosh Kalantar; Ghasem Ghalamfarsa; Mehdi Mohebali; Gholamreza Hatam
Journal:  Pathog Glob Health       Date:  2019-05-17       Impact factor: 2.894

5.  Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis.

Authors:  Manas Ranjan Dikhit; Akhilesh Kumar; Sushmita Das; Budheswar Dehury; Ajaya Kumar Rout; Fauzia Jamal; Ganesh Chandra Sahoo; Roshan Kamal Topno; Krishna Pandey; V N R Das; Sanjiva Bimal; Pradeep Das
Journal:  Front Immunol       Date:  2017-12-14       Impact factor: 7.561

6.  Analysis of the Antigenic and Prophylactic Properties of the Leishmania Translation Initiation Factors eIF2 and eIF2B in Natural and Experimental Leishmaniasis.

Authors:  Esther Garde; Laura Ramírez; Laura Corvo; José C Solana; M Elena Martín; Víctor M González; Carlos Gómez-Nieto; Aldina Barral; Manoel Barral-Netto; José M Requena; Salvador Iborra; Manuel Soto
Journal:  Front Cell Infect Microbiol       Date:  2018-04-05       Impact factor: 5.293

7.  Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Authors:  Semra Palić; Patrick Bhairosing; Jos H Beijnen; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

8.  A comparative analysis of secreted protein disulfide isomerases from the tropical co-endemic parasites Schistosoma mansoni and Leishmania major.

Authors:  Adriana E Miele; Sofiane Badaoui; Lorenzo Maugliani; Romain Salza; Giovanna Boumis; Silvia Chichiarelli; Bertrand Duclos; Sylvie Ricard-Blum
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

9.  Investigation of the antigenicity and protective efficacy of Leishmania promastigote membrane antigens in search of potential diagnostic and vaccine candidates against visceral leishmaniasis.

Authors:  Sarfaraz Ahmad Ejazi; Smriti Ghosh; Anirban Bhattacharyya; Mohd Kamran; Sonali Das; Sudipta Bhowmick; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  Parasit Vectors       Date:  2020-05-30       Impact factor: 3.876

10.  Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.

Authors:  Sumit Joshi; Narendra K Yadav; Keerti Rawat; Chandra Dev P Tripathi; Anil K Jaiswal; Prashant Khare; Rati Tandon; Rajendra K Baharia; Sanchita Das; Reema Gupta; Pramod K Kushawaha; Shyam Sundar; Amogh A Sahasrabuddhe; Anuradha Dube
Journal:  Front Microbiol       Date:  2016-03-22       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.